IMR Press / FBE / Volume 8 / Issue 3 / DOI: 10.2741/E774

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Randomized controlled trials for Alzheimer disease and Parkinson disease

Show Less
1 Geriatric Clinic and Laboratory of Movement Analysis, Geriatric and Rehabilitation Department, University Hospital of Parma, Via Gramsci 14, I-431126 Parma, Italy
2 Internal Medicine and Critical Subacute Care Unit, Parma University Hospital, Via Gramsci 14, I-431126 Parma, Italy
3 Department of Clinical and Experimental Medicine, University of Parma, Via Gramsci 14, I-431126 Parma, Italy

*Author to whom correspondence should be addressed.

Academic Editor: Christian Saleh

Front. Biosci. (Elite Ed) 2016, 8(3), 378–389; https://doi.org/10.2741/E774
Published: 1 June 2016
(This article belongs to the Special Issue The polyhedral aspects of dementia)
Abstract

The continuous increase in elderly and oldest-old population, and subsequent rise in prevalence of chronic neurological diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD), are a major challenge for healthcare systems. These two conditions are the most prevalent neurodegenerative diseases in older persons and physicians should engage treatment for these patients. In this field, Randomized Clinical Trials (RCTs) specifically focused on elderly populations are still lacking. The aim of this study was to identify RCTs conducted among AD and PD and to examine the difference between mean age of enrollment and incidence of these two neurodegenerative diseases. We found that the scenario is different between PD and AD. In particular, the enrollment for PD trials seems to include younger persons than AD, although the incidence of both diseases is similar and highest after 80 years old. The consequence of these results could influence conclusive guidelines of treatment in older parkinsonian patients.

Keywords
Review
Alzheimer’s Diseases
Parkinson’s Disease
Randomized Clinical Trials
Evidence Based Medicine
Share
Back to top